The story
- Researchers at Kindai University in Osaka found that oral administration of arginine — a naturally occurring amino acid widely available as an over-the-counter supplement — significantly suppressed the buildup of amyloid-beta proteins in animal models of Alzheimer's disease.
- In mouse models, arginine reduced plaque deposition, lowered levels of insoluble amyloid-beta in the brain, decreased the expression of pro-inflammatory genes, and improved behavioural performance on cognitive tests.
- Current antibody-based Alzheimer's treatments cost tens of thousands of dollars annually and carry risks including brain swelling and bleeding. Arginine, by contrast, is inexpensive and has a strong existing safety record in humans.
- Arginine works as a "chemical chaperone" — a substance that helps proteins maintain their proper shape rather than clumping into the toxic aggregates that damage neurons.
- Researchers emphasize that the dosage used in this study was optimized for research and does not correspond to commercial supplements — human trials have not yet begun.
- The findings were published in the peer-reviewed journal Neurochemistry International and are being followed as one of the most promising low-cost Alzheimer's research leads in recent years.
"
Its strong safety record and low cost make it a promising candidate for rapid therapeutic repurposing.
— Neuroscience News, summarising Kindai University findings
Sources